Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent (NYSE: A) will showcase next‑generation automated workflow solutions at SLAS2026 in Boston, Feb 7–11, 2026. The company will demo integrated imaging, robotics partnerships, AI‑driven CrossLab Connect enhancements, a new Cytation imaging platform preview, ProteoAnalyzer Software Security Module, and updated Bravo liquid‑handling protocols.
The exhibits include multi‑vendor integrations with ABB Robotics, HighRes Biosolutions, Biosero, and Unite Labs, two exhibitor tutorials, a spotlight presentation, and participation in conference panels.
Agilent (NYSE: A) will report first-quarter fiscal 2026 results after market close on Feb. 25, 2026 and will host a listen-only conference call/webcast at 1:30 p.m. PST the same day.
A recording will be available on the company's investor relations site for 90 days. Agilent reported $6.95 billion revenue in fiscal 2025 and employs about 18,000 people worldwide.
Agilent (NYSE: A) launched the Agilent S540MD Slide Scanner System on January 23, 2026, a whole slide imaging scanner for high-volume digital pathology in key European markets. Engineered for speed and scalability, the system holds up to 540 slides, supports continuous loading, standard rack compatibility, automated scanning modes, and AI-assisted tissue detection. The scanner is an Agilent-branded version of the Hamamatsu NanoZoomer S540MD and will be available as IVD initially in Germany, France, Belgium, Spain, Austria, Luxembourg, Italy, the UK, and Switzerland, with further European expansion and milestones planned for 2026.
Agilent (NYSE: A) announced that CEO Padraig McDonnell and CFO Adam Elinoff will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 13, 2026, 9:00–9:40 a.m. PST. A live audio webcast and replay will be available via Agilent’s investor relations website.
Agilent reported $6.95 billion in revenue for fiscal year 2025 and employs approximately 18,000 people worldwide. The presentation likely will review recent performance and strategic priorities; investors can access the webcast and contact investor relations for more information.
Agilent (NYSE: A) released a 21 CFR Part 11 compliance software upgrade for the xCELLigence RTCA eSight system on December 1, 2025. The software adds a compliance license and enhanced security features—secure user authentication, electronic signatures, and complete audit trails—enabling deployment in GMP-regulated manufacturing and quality control as well as drug discovery labs.
The upgrade is positioned to support continuity from early research to production, improve audit readiness, and simplify regulatory submissions while maintaining workflow efficiency and data quality.
Agilent (NYSE: A) reported Q4 FY2025 revenue $1.86B, up 9.4% reported and up 7.2% on a core basis versus Q4 2024, with GAAP EPS of $1.53 (up 25% YoY) and non-GAAP EPS of $1.59 (up 9% YoY). Full FY2025 revenue was $6.95B, up 6.7% reported; FY2025 GAAP EPS was $4.57 and non-GAAP EPS was $5.59. Management provided FY2026 guidance of $7.3B–$7.4B revenue (up 5%–7% reported) and non-GAAP EPS $5.86–$6.00; Q1 FY2026 revenue guidance is $1.79B–$1.82B with non-GAAP EPS $1.35–$1.38.
Agilent (NYSE: A) announced a quarterly cash dividend of 25.5 cents per share. The dividend is payable on Jan. 28, 2026 to shareholders of record at the close of business on Jan. 6, 2026. The company said timing and amounts of future dividends remain subject to the board of directors’ determination and approval.
Agilent reported $6.51 billion in revenue for fiscal year 2024 and employs approximately 18,000 people worldwide. The release includes customary forward-looking statement language about risks and uncertainties related to the dividend program.
Agilent Technologies (NYSE: A) announced the Altura Ultra Inert HPLC columns, a new product line aimed at biotherapeutics analysis including peptide GLP-1 and oligonucleotide workflows. The release highlights faster conditioning, improved peak shape, enhanced sensitivity, and a fully inert sample flow path designed for demanding QC and development labs.
Agilent claims up to 2x sensitivity, 3x signal-to-noise ratio, and, when paired with the Agilent 1290 Infinity III Bio LC, up to 30x higher peak area; an external test cited a ~30% sensitivity increase and reduced peak tailing on acidic peptides.
Agilent (NYSE: A) will participate in Citi’s 2025 Global Healthcare Conference on Dec. 4, 2025. Chief Enterprise Transformation Officer Tom Callihan and Head of Investor Relations Tejas Savant will take part in a fireside chat from 9:00 to 9:45 a.m. EDT in Miami.
A live audio webcast and replay will be available on Agilent’s investor relations website. Agilent reported $6.51 billion revenue in fiscal year 2024 and employs approximately 18,000 people worldwide.
Lunit (KRX:328130.KQ) and Agilent (NYSE:A) announced a nonexclusive collaboration on Sept 22, 2025 to co-develop AI-powered companion diagnostic (CDx) solutions for complex biomarker assays.
The partnership will combine Lunit's AI algorithms and Agilent's tissue-based diagnostic assays, initially targeting research and clinical-trial use to improve biomarker accuracy and support pharma CDx development. Lunit noted its FDA-cleared Lunit INSIGHT suite is used at over 7,000 medical institutions in more than 65 countries.